1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Oncology Research Digest H1 2014

Oncology Research Digest H1 2014

  • August 2014
  • -
  • TBRC Business Research
  • -
  • 19 pages

The Oncology Research Digest is a digest of all the most important research in the oncology market each quarter, and available as an annual subscription. It covers areas such as biosimilars, novel immunotherapies, non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer, ovarian cancer and drugs such as Rituxan, Avastin, Herceptin, Traceva, Xeloda, Gleevec, Revlimid, Alimta, Velcade. It is gathered from over 50 sources including associations, consultants, market intelligence companies, investment banks, and industry participants.

Updated quarterly, the Digest allows you to:
- Quickly update yourself on the latest research findings, gathered and organised for you.
- Get our Expert Analysts’ perspectives on the latest research.
- Link through to the original research to review or purchase.

Oncology Research Digest H1 2014 finds that the cancer market is successfully adapting to challenges. Patent expires and payer pressures have led to relatively slow growth in the cancer market in the last five years, and this will continue to be a feature. However the launch of new drugs for the treatment of various types of cancers including lung, blood and pancreatic cancer are expected to drive growth. New drugs will also drive global markets for Non-Small Cell Lung Cancer, Anti- Cancer and Lymphocytic Cancer. These new products will change the shape of the market, with players such as Johnson and Johnson coming to the fore.

In terms of geographies, the US market continues to lead with the prices of cancer drugs and treatment costs increasing due to the shift in the US healthcare system. The Asia Pacific region looks the most attractive geography in terms of potential, however the Indian and Chinese markets remain hindered by local market factors.

Some highlights from the Digest include:
- Global Prostate Cancer Therapeutics Market Has Good Commercial Potential
- Physicians in China Prescribe Less Expensive Drugs First
- Caribbean Countries Present Opportunities for Pharmaceutical Companies
- Johnson & Johnson to Emerge as a Key Oncology Player
- Shift in the US Health Care Systems Increased the Cost of Cancer Treatment
- Branded Drugs Adoption to Drive Breast Cancer Market

Table Of Contents

Oncology Research Digest H1 2014
1_Global Oncology Research
1.1._Global Oncology Spending Growth Declined (2008-2013)
1.2._Who Are The Leading Players In the Cancer Drugs Market in 2013 and 2018?
1.3._Johnson and Johnson to Emerge as a Key Oncology Player
1.4._New Drugs Launch Will Expand Global Market Size for Anti-Cancer Kinase Inhibitor Drugs
1.5._Biosimilars Contribution in Biologics Market for Oncology Treatment Remains Low
1.6._Immunotherapies Have Potential for Non-Small Cell Lung Cancer Treatment
1.7._Global Cancer Immunotherapy Market Expected To Soar To 2022
1.8._Pancreatic Cancer Treatment Market Forecast to Grow Slowly
1.9._New Drugs to Drive Chronic Lymphocytic Leukemia Treatment Market
1.10._Bladder Cancer Market Will Grow Slowly
1.11._Breast Cancer the Second Most Common Cancer Globally
1.12._Branded Drugs Adoption to Drive Breast Cancer Market
1.13._Ovarian Cancer Therapeutics Market Growth Minimized By Approved Therapies Shortage
1.14._Global Prostate Cancer Therapeutics Market Has Good Commercial Potential
1.15._Orphan Drugs Market Nearly Half of Global Cancer Market In 2012
1.16._Strong Growth Predicted For Orphan Drugs Market
2_The Americas Oncology Research
2.1._Prices of Cancer Drugs Increasing In the USA
2.2._Shift in the US Health Care Systems Have Increased the Cost of Cancer Treatment
2.3._Caribbean Countries Present Opportunities for Pharmaceutical Companies
2.4._Prostate Cancer: The Second Leading Cause of Cancer Death in Men in the USA
3_Asia Pacific Oncology Research
3.1._Asia Accounts for Nearly Half of the Total Global Cancer Incidence
3.2._Asian NSCLC Treatment Market Will Grow Only Marginally In Spite of Expected Drug Launches
3.3._Increased Adoption of Branded Drugs Expands Breast Cancer Market in Asia-Pacific Region
3.4._China's Gastric Cancer Drug Market Increased after Herceptin's Approval to Treat Gastric Cancer
3.5._Physicians in China Prescribe Less Expensive Drugs First
3.6._Absence of Reimbursement Limits Breast Cancer Treatment in China
3.7._Issues for Foreign Pharmaceutical Companies in China
3.8._China's Reported Prostate Cancer Rates among the Lowest in the World
3.9._Low Affordability of Cancer Treatment in China Affects Cure Rates
3.10._Shortage of Oncologists in India
4_Europe Oncology Research
4.1._Breast Cancer the Most Common Type of Cancer in Europe
4.2._Breast Cancer More Than 30% of All Cancers in Females in the UK
Appendix
Abbreviations
Currencies
About Oncology Research Digest
Get Oncology Research Digest Today
The Business Research Company


Companies Mentioned
Goldman Sachs, UBS, Morgan Stanley, Credit Suisse, Citigroup, Nomura, black rock, old mutual

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.